CannaPhytica BioMed (CannaPhytica) is a Cannabis focused biotechnology company with 5 years of unique provenance in the cannabis industry and extensive ties with the lucrative German and European markets. CannaPhytica was formed to bring several income streams under one roof –research and development, product development, import – export and wholesale distribution into the German market.
CannaPhytica is building on many years of experience in the medicinal cannabis and pharmaceutical sectors, becoming one of the fastest growing opportunities in the global healthcare sector.
Our state-of-the-art facilities in Schwerin allow us to fully integrate and control the supply chain of our cannabis-based products from growing to distribution. Our team of experts includes pharmacists, scientists, and medical professionals who have extensive knowledge and experience in the cannabis industry.
Established in 2017, Cannaphytica is the holder of an EU-GDP license and is approved to supply generic pharmaceuticals in finished dosage forms (FDFs), including active pharmaceutical ingredients (APIs) and other healthcare products. Along with the manufacturing of pharmaceuticals, the company also specializes in trading pharmaceuticals and medical care products.
At CannaPhytica, we are committed to adhering to Good Manufacturing Practices (GMP) to ensure the safety and efficacy of our products. Our full supply chain control and strict quality standards allow us to deliver innovative, high-quality cannabis-based products that meet the quality standards established by Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the Federal Institute for Drugs and Medical Devices in Germany. Our partners that grow for us are professional and all GMP compliant and GACP certified, and CannaPhytica monitors the process from the start until it reaches the German or EU market.